Back to search

National and Kapodistrian University of Athens

Μελέτη και κλινική αξιολόγηση του γονιδίου NES1 (KLK10) καθώς και των εναλλακτικών μεταγράφων του στον καρκίνο του παχέος εντέρου

Abstract

dc:description

Colon cancer is the most frequent malignant disease of the digestive system in USA and Europe. In our country, colon cancer ranked fourth among causes of death from neoplasms. The biomarkers used in modern clinical practice are the Carcinoembryonic Antigen (CEA), the Carbohydrate Antigen 19-9 (CA 19-9), the 72-4 Cancer Antigen (CA72-4) and the Tissue plasminogen activator (PLAT). Although several prognostic and predictive markers for colon cancer have been recognized, very few of them are currently used in clinical practice.The human tissue kallikrein gene family is the largest contiguous gene family of proteases in the human genome, with no intervention from other genes. It is a very attractive field of study, as one of its members, the famous PSA/KLK3, is the most accepted and widely used cancer biomarker, until today. Studies have suggested other family members as potential biomarkers for prognosis or/and prediction of colon cancer, including KLK4 and KLK7, at mRNA level, and KLK4, KLK7 and KLK11, at protein level. KLK10 gene is a new member of the kallikrein tissue family. Several studies have been conducted to assess the potential role of KLK10 as a tumor marker. Due to its higher levels in tumor tissues and serum of patients with ovarian cancer, KLK10 has been proposedas diagnostic and prognostic marker for ovarian cancer, in combination with the already used marker CA125, for increased diagnostic sensitivity. In this thesis, we performed clinical evaluation of the KLK10 gene for its possible application as a new prognostic marker for colorectal cancer. The mRNA expression study was performed with conventional RT-PCR and quantitative PCR methodology in real-time (real-time PCR), and the protein was detected and measured by Enzyme-Linked Immunosorbent Assay (ELISA). Analytical protocols were developed to determine the mRNA expression of KLK10 gene in colorectal cancer based on reverse transcription (RT), polymerase chain reaction (PCR) and quantitative real-time PCR (real-time PCR) methodology. Detection and quantification of protein KLK10 performed by Enzyme-Linked Immunosorbent Assay (ELISA). There weren’t any ready kit to be used for the abovementioned experiments, all the assays were developed in our lab, so we also performed quality control in order to ensure the reliability of the results. We collected a statistically significant size from cancerous and non- cancerous colon tissue samples (194 tissues), from patients with complete clinical history. For the analysis of data, an extensive biostatistical analysis was performed. We used parametric and nonparametric methodologies, ROC analysis, Kaplan-Meier survival analysis, as well as univariate and multivariate Cox regression analysis. The results obtained showed that the mRNA expression of the KLK10 gene is statistically associated with several clinicopathological parameters, including Duke’s Stage (P=0.036), Grade (P=0.025), lymph nodes status (P=0.046) and distant organs metastasis (P=0.027). The Kaplan Meier survival analysis showed statistically significantly shorterpossibility of disease-free (DFS) and overall survival (OS) of patients with positive KLK10mRNA expression (P=0.014 and P=0.020, respectively). The expression of KLK10 protein was statistically significant higher in tumor samples than in normal counter parts (P<0.001). In conclusion, the cancerous colon tissues examined showed a higher expression of KLK10gene. The over-expression of this appears to be associated with poor prognosis in patients with colon cancer and may constitute a useful novel molecular biomarker. We then cultured colorectal adenocarcinoma cell line HT-29, for which we constructed viability curves, followed by treatment with chemotherapy drugs used in systematic treatment of colon cancer (fluorouracil, oxaliplatin), as well as with other widely used cancer drugs (taxotere, cisplatin, gemcitabine). For the first time, after the treament with the administered agent, we removed the agent and we continued the cell culture, in order to evaluate whether the cells continue to die or if they revert to normal cell division,when the drug is removed. Then, we evaluated the mRNA expression profiles of KLK10 gene, as well as other genes involved in apoptosis: BCL2, BCLX, MCL1, BAX, BAK1, BIM,BID, PUMA (BBC3), NΟΧΑ (PMAIP1), BIRC5 (Survivin), and P21 (CDKN1A). KLK10 mRNA expression levels were elevated, after the treatment with fluorouraciland cisplatin, while smaller scale changes were observed with the treatment with other drugs. Finally, what was very interesting, was the fact that KLK10 mRNA pattern of expression followed the mRNA pattern of expression of the proapoptotic NOXA gene. Regarding the BCL2 family members, depending on the chemotherapeutic agentused, other members expression levels increased, while others decreased and others remained the same. The transcriptional activation of some members in each treatment with cytotoxic agent, however, suggests that, depending on the stimulus, the proapoptotic members begin their path to apoptosis. The position of each molecule may be of strategic importance in order to ensure the pathway of apoptosis. This could reveal a unified role inproapoptotic BH3-only family members. Perhaps such a mechanism is established by the transcriptional activation of different members of the family, during the treatment with different chemotherapeutic agents. It is worth noting, finally, that the mRNA expression of the antiapoptotic BCL2 gene was down regulated in the presence of all the above mentioned cytotoxic agents, which is in agreement with previous studies where over expression of the gene was combined with tolerance to chemotherapy. A second important point that emerges from this study, is the use of taxotere and cisplatin in colon cancer chemotherapy. From treatment with both agents, the cells continued to die, even after their removal from the flask. Finally, the expression of the KLK10 gene, at both mRNA and protein level, has features of an unfavorable prognostic marker for colon cancer, as it is associated with shorter disease free and overall survival, and this is the most important result of this thesis.Its transcriptional activation after treatment with chemotherapeutic agents, perhaps assigns it a possible role as a biomarker for response to chemotherapy. The understanding of regulation mechanisms and the discovery of the physiological substrate of this enzyme, willlead to its evaluation as a potential target for colon cancer treatment.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Alexopoulou, Dimitra
  • Αλεξοπούλου, Δήμητρα

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44216

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Alexopoulou, Dimitra; Αλεξοπούλου, Δήμητρα. Μελέτη και κλινική αξιολόγηση του γονιδίου NES1 (KLK10) καθώς και των εναλλακτικών μεταγράφων του στον καρκίνο του παχέος εντέρου. National and Kapodistrian University of Athens, 2014. http://hdl.handle.net/10442/hedi/44216